View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 8, 2019

Tisotumab vedotin shows promise in treating six cancer types

A Phase I/II global clinical trial demonstrated that a new drug called tisotumab vedotin (TV), which uses ‘Trojan horse’ approach to enter into tumour cells, can treat six different types of cancer.

A Phase I/II global clinical trial has demonstrated that a new drug called tisotumab vedotin (TV) can treat six different types of cancer.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

TV uses a ‘Trojan horse’ approach to enter tumours and release a toxic substance, killing the cancerous cells from within. It consists of a toxic drug linked to the tail end of an antibody, which is engineered to identify the tissue factor receptor.

Funded by biotechnology companies Genmab and Seattle Genetics, the trial was led by the Institute of Cancer Research (ICR) in the UK.

This receptor is known to be present in high levels on the surface of many cancers cells and associated with worse survival.

Patients with advanced, drug-resistant cancers were observed to respond to the drug, with their tumours shrinking or stopping growing.

The trial initially enrolled 27 patients and later expanded to include an additional 120 participants who stopped responding to conventional treatments.

“What is so exciting about this treatment is that its mechanism of action is completely novel.”

It was intended to evaluate the drug’s safety and determine its right dose, as well as evaluate if it is acting on the right target and effect on tumours.

Treatment with tisotumab vedotin was found to elicit responses in 27% bladder cancer patients, 26.5% of those with cervical cancer, 14% with ovarian cancer, 13% with oesophageal, 13% with non-small cell lung, and 7% with endometrial cancer.

Data revealed that responses lasted an average of 5.7 months and up to 9.5 months in certain patients. Prostate cancer patients did not respond to the new therapy, however.

The main side effects observed during the trial were nausea, fatigue, nose bleeds, and eye problems.

ICR Cancer Research professor Johann de Bono said: “What is so exciting about this treatment is that its mechanism of action is completely novel, it acts like a Trojan horse to sneak into cancer cells and kill them from the inside.

“Our early study shows that it has the potential to treat a large number of different types of cancer, and particularly some of those with very poor survival rates.”

The drug is currently being studied in other cancer types such as pancreatic, squamous cell lung and head and neck cancers. It is also undergoing a Phase II trial as a second-line treatment for cervical cancer.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena